Is It Too Late to Buy Eli Lilly?

It is hard to explain how impressive Eli Lilly's (NYSE: LLY) GLP-1 success has been. In 2025, sales of the company's Mounjaro and Zepbound rose 99% and 175%, respectively. The two drugs have grown so rapidly that they now account for 56% of Eli Lilly's revenues. There's likely to be more growth ahead, too, as demand for these weight loss drugs remains strong. However, it may still be too late for you to buy Eli Lilly. Here's why. Will AI create the world's first trillionaire? Our team just released a repor ...